Liquidia CFO Michael Kaseta Takes On Additional Role Of COO
(RTTNews) - Biopharmaceutical company Liquidia Corp. (LQDA) announced Friday updates and promotions to its operations leadership in advance of the potential approval and launch of YUTREPIA (treprostinil) inhalation powder.
Michael Kaseta, Chief Financial Officer (CFO), has added the role of Chief Operating Officer (COO) to his responsibilities effective on January 15, 2023.
In his expanded role as COO/CFO, Kaseta will be responsible for several key areas in addition to finance, including human resources, information technology, quality, manufacturing, and business strategy.
In connection with this change, Michael Hunter was also promoted to Senior Vice President of Manufacturing Operations, where he will manage all day-to-day manufacturing and supply chain operations internally and externally.
Simultaneously, former Chief Operations Officer, Robert Lippe, will transition out of the Company over a three-month period.
Liquidia Says Court Denies United Therapeutics' Motion For Injunction To Block Launch Of YUTREPIA
TSX Down Marginally In Lackluster Trade
Swiss Market Settles Flat
European Markets Close On Mixed Note After Cautious Session
Dollar Extends Losses As Markets Cling On To Fed Cut Hopes
U.S. Homebuilder Confidence Edges Slightly Lower In August
Indian Rupee Rises To 2-week High On GST Reforms Push
